Considerable progress has been made in the treatment of patients with renal cell carcinoma,
with innovative surgical and systemic strategies revolutionising the management of this …

Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …

Thyroid hormone deficiency can have important repercussions. Treatment with thyroid
hormone in replacement doses is essential in patients with hypothyroidism. In this review …

With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall
survival has improved, and patients are being treated continuously for increasingly long …

BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important
antitumor activity in metastatic renal cell carcinoma (mRCC). Hypothyroidism constitutes a …

Despite their inherent selectivity, targeted therapies such as tyrosine kinase inhibitors (TKIs)
can cause unusual adverse effects. Sunitinib and sorafenib are multitargeted TKIs that have …

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-
resistant or-intolerant gastrointestinal stromal tumours (GIST). Several studies have …

Thyrotoxicosis is the clinical manifestation of excess thyroid hormone action at the tissue
level due to inappropriately high circulating thyroid hormone concentrations …

This article reviews evidence that causally links hormonal disorders with hepatobiliary
disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream …

Unlike cytotoxic agents that indiscriminately affect rapidly dividing cells, newer
antineoplastic agents such as targeted therapies and immunotherapies are associated with …